{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:58:53Z","timestamp":1763017133435},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T00:00:00Z","timestamp":1313452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Bone marrow transplantation (BMT) using human leukocyte antigen (HLA)\u2010matched sibling donors can be curative for children with sickle cell anemia (SCA). However, minimal data exist regarding availability of HLA\u2010identical matched siblings for transplant\u2010eligible children, and family interest in pursuing transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed a pediatric SCA cohort receiving chronic transfusions between July 2004 and January 2011. Data were analyzed regarding the number of full siblings and half\u2010siblings, availability, and family interest in HLA testing the full siblings, and interest in proceeding with HLA\u2010matched transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 113 patients, 46 (41%) had at least 1 full sibling and 40 (35%) had an unaffected full sibling who could serve as a BMT donor. The families of 23 of these patients (58%) agreed to HLA\u2010type sibling, 8 of whom (35%) were matched. Transfusion indications for families agreeing to HLA typing included stroke (46%) abnormal TCD (29%), acute chest syndrome (21%), and other CNS reasons (4%). Common reasons to decline HLA typing or transplantation included fear of the process, toxicities of the procedure, and comfort with current quality of life on transfusions. Only 8 of 113 (7%) were eligible for matched BMT, and only 3 (3%) underwent HLA\u2010matched transplantation. Two unmatched children received haploidentical transplantation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Most families of children with SCA on chronic transfusions choose to proceed with HLA typing. However, when a matched sibling was identified, most families declined to proceed with matched\u2010sibling transplantation. Discussing BMT as a treatment option, offering HLA typing and identifying barriers may improve acceptance of this treatment modality. Pediatr Blood Cancer 2012; 58: 611\u2013615. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.23304","type":"journal-article","created":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T21:32:24Z","timestamp":1313530344000},"page":"611-615","source":"Crossref","is-referenced-by-count":31,"title":["Bone marrow transplant options and preferences in a sickle cell anemia cohort on chronic transfusions"],"prefix":"10.1002","volume":"58","author":[{"given":"Eileen N.","family":"Hansbury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell E.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banu","family":"Aygun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,16]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06592.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cppeds.2007.10.002"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652408786241393"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198409203111207"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608083350601"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701291"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-079665"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21570"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-251348"},{"key":"e_1_2_6_11_2","first-page":"100","article-title":"Barriers to bone marrow transplantation for sickle cell anemia","volume":"2","author":"Walters MC","year":"1996","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-332510"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111073251905"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.11.007"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0394"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-9684(15)31069-5"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20903"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181b83cab"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e31817e4a44"},{"key":"e_1_2_6_20_2","article-title":"Development of the PedsQL sickle cell disease module items: Qualitative methods","author":"Panepinto JA","year":"2011","journal-title":"Qual Life Res"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3078"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23029"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23028"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/JCE200617107","article-title":"Child\u2010to\u2010parent bone marrow donation for treatment of sickle cell disease","volume":"17","author":"Anderson\u2010Shaw L","year":"2006","journal-title":"J Clin Ethics"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.203"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2007.00725.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/07357900902892780"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.10.005"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.12.022"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-261123"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23304","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.23304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:33:46Z","timestamp":1697632426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.23304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,16]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/pbc.23304"],"URL":"https:\/\/doi.org\/10.1002\/pbc.23304","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,16]]}}}